{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:54:46Z","timestamp":1790934886868,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.ygyno.2009.02.007","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T04:30:57Z","timestamp":1236227457000},"page":"210-215","source":"Crossref","is-referenced-by-count":42,"title":["A phase II study of GM-CSF and rIFN-\u03b31b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer"],"prefix":"10.1016","volume":"113","author":[{"given":"Kathleen M.","family":"Schmeler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Vadhan-Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro T.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin M.","family":"Apte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revathy B.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith K.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Levenback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2009.02.007_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2009.02.007_bib3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/annonc\/mdi147","article-title":"Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study","volume":"16","author":"Gonzalez-Martin","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib4","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib5","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ygyno.2006.09.023","article-title":"Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer","volume":"104","author":"Strauss","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/annonc\/mdl376","article-title":"Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial","volume":"18","author":"Ferrero","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib7","first-page":"47","article-title":"Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor","volume":"18","author":"Triozzi","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ygyno.2009.02.007_bib8","first-page":"7318","article-title":"Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells","volume":"50","author":"Allavena","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2009.02.007_bib9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1126\/science.3083507","article-title":"Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor","volume":"232","author":"Grabstein","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2009.02.007_bib10","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1200\/JCO.2000.18.8.1614","article-title":"Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor","volume":"18","author":"Spitler","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11912-003-0106-7","article-title":"Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored","volume":"5","author":"Buter","year":"2003","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2009.02.007_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.1996.14.2.343","article-title":"Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy","volume":"14","author":"Pujade-Lauraine","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib13","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1054\/bjoc.1999.1053","article-title":"Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial","volume":"82","author":"Windbichler","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.02.007_bib14","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1525-1438.2006.00622.x","article-title":"Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I\/II study","volume":"16","author":"Marth","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2009.02.007_bib15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2008.01.005","volume":"109","author":"Alberts","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib16","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1200\/JCO.1992.10.8.1266","article-title":"Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level","volume":"10","author":"Vadhan-Raj","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib17","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2009.02.007_bib19","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2007.08.092","article-title":"Clinical trial endpoints in ovarian cancer: report of an FDA\/ASCO\/AACR Public Workshop","volume":"107","author":"Bast","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","article-title":"Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy","volume":"47","author":"Trotti","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2009.02.007_bib22","series-title":"Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales, Center on Outcomes, Research and Education (CORE): Evanston Northwestern Healthcare and Northwestern University, 1997","author":"Cella","year":"1997"},{"key":"10.1016\/j.ygyno.2009.02.007_bib23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib24","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1200\/JCO.2000.18.16.2972","article-title":"Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma","volume":"18","author":"Motzer","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib25","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1200\/JCO.2003.02.136","article-title":"Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population","volume":"21","author":"Cella","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib26","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1046\/j.1525-1438.2003.13331.x","article-title":"Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma","volume":"13","author":"Melichar","year":"2003","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2009.02.007_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1479-5876-4-16","article-title":"Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin","volume":"4","author":"Apte","year":"2006","journal-title":"J. Transplant. Med."},{"key":"10.1016\/j.ygyno.2009.02.007_bib28","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.1158\/0008-5472.CAN-07-0696","article-title":"Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors","volume":"67","author":"Stavenhagen","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2009.02.007_bib29","first-page":"1375","article-title":"Randomized phase II clinical trials","volume":"69","author":"Simon","year":"1985","journal-title":"Cancer Treat Rep."},{"key":"10.1016\/j.ygyno.2009.02.007_bib30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1008240421028","article-title":"Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients","volume":"8","author":"Eisenhauer","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib31","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical features of hypersensitivity reactions to carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.02.007_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000055363","article-title":"Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience","volume":"61","author":"Polyzos","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2009.02.007_bib33","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ygyno.2006.04.002","article-title":"Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients","volume":"103","author":"Navo","year":"2006","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809000833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809000833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T08:31:33Z","timestamp":1558168293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809000833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0090825809000833"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.02.007","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}